Original title: New batch of anti-cancer drugs reduced value-added tax
News from our newspaper (Reporter Zhang Qin) In order to encourage the development of the pharmaceutical industry and reduce the cost of medication for patients, another batch of anti-cancer drugs and rare disease drugs will implement relevant value-added tax policies from this month.
According to the latest announcement issued by the Ministry of Finance, the General Administration of Customs, the State Administration of Taxation, and the Food and Drug Administration, starting from October 1, 2020, the new batch of anti-cancer drugs and rare disease drugs will be in accordance with the "National Drug Administration Provisions of the Notice of the Ministry of Finance on the Value-Added Tax Policy for Anti-cancer Drugs (Caishui (2018) No. 47), and the ``Notice of the Ministry of Finance and the General Administration of Customs and the State Administration of Taxation and Drug Administration on the Value-Added Tax Policy for Drugs for Rare Diseases'' (Caishui (2019) No. 24) Implement relevant value-added tax policies.
The above-mentioned related policies are clear. Starting from March 1, 2019, general value-added taxpayers who produce, sell, wholesale and retail rare disease drugs can choose to calculate and pay value-added tax at a 3% collection rate in accordance with the simplified method.
After the above-mentioned taxpayers choose the simple method to calculate and pay the value-added tax, they cannot change it within 36 months.
Starting from March 1, 2019, import value-added tax on imported rare disease drugs will be reduced by 3%.
A reporter from the Beijing Youth Daily learned that the value-added tax reduction drugs include 45 anti-cancer drug preparations, including dacomitinib tablets, a targeted treatment drug for non-small cell lung cancer, and fruquintinib capsules, a drug for metastatic colorectal cancer. Raw materials, as well as 14 rare-disease pharmaceutical preparations, including teriflunomide tablets for the treatment of multiple sclerosis, and Noxinassen sodium injection for the treatment of spinal muscular atrophy.